


**Amendments to the claims:**

**We Claim:**

**What is claimed is:**


1. A method of inhibiting cathepsin S, comprising administering to a patient in need thereof an effective amount of a compound of Formula I:





I

wherein:

R<sup>1</sup> is selected from the group consisting of:



R<sup>2</sup> is selected from the group consisting of: H, C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl-C<sub>0-6</sub>alkyl, Ar-C<sub>0-6</sub>alkyl, Het-C<sub>0-6</sub>alkyl, R<sup>9</sup>C(O)-, R<sup>9</sup>C(S)-, R<sup>9</sup>SO<sub>2</sub>-, R<sup>9</sup>OC(O)-,



Predecessor Serial No.: 10/258,053

Group Art Unit No.:

$R^3$  is selected from the group consisting of: H, C<sub>1</sub>-6alkyl, C<sub>3</sub>-6cycloalkyl-C<sub>0</sub>-6alkyl, C<sub>2</sub>-6alkenyl, C<sub>2</sub>-6alkynyl, HetC<sub>0</sub>-6alkyl, ArC<sub>0</sub>-6alkyl, Ar-ArC<sub>0</sub>-6alkyl, Ar-HetC<sub>0</sub>-6alkyl, Het-ArC<sub>0</sub>-6alkyl, and Het-HetC<sub>0</sub>-6alkyl;

$R^3$  and  $R'$  may be connected to form a pyrrolidine, piperidine or morpholine ring;

$R^4$  is selected from the group consisting of: H, C<sub>1</sub>-6alkyl, C<sub>3</sub>-6cycloalkyl-C<sub>0</sub>-6alkyl, Ar-C<sub>0</sub>-6alkyl, Het-C<sub>0</sub>-6alkyl, R<sup>5</sup>C(O)-, R<sup>5</sup>C(S)-, R<sup>5</sup>SO<sub>2</sub>-, R<sup>5</sup>OC(O)-, R<sup>5</sup>R<sup>13</sup>NC(O)-, and R<sup>5</sup>R<sup>13</sup>NC(S)-;

$R^5$  is selected from the group consisting of: H, C<sub>1</sub>-6alkyl, C<sub>2</sub>-6alkenyl, C<sub>2</sub>-6alkynyl, C<sub>3</sub>-6cycloalkyl-C<sub>0</sub>-6alkyl, Ar-C<sub>0</sub>-6alkyl and Het-C<sub>0</sub>-6alkyl;

$R^6$  is selected from the group consisting of: H, C<sub>1</sub>-6alkyl, C<sub>3</sub>-6cycloalkyl-C<sub>0</sub>-6alkyl, Ar-C<sub>0</sub>-6alkyl, and Het-C<sub>0</sub>-6alkyl;

$R^7$  is selected from the group consisting of: H, C<sub>1</sub>-6alkyl, C<sub>3</sub>-6cycloalkyl-C<sub>0</sub>-6alkyl, Ar-C<sub>0</sub>-6alkyl, Het-C<sub>0</sub>-6alkyl, R<sup>10</sup>C(O)-, R<sup>10</sup>C(S)-, R<sup>10</sup>SO<sub>2</sub>-, R<sup>10</sup>OC(O)-, R<sup>10</sup>R<sup>14</sup>NC(O)-, and R<sup>10</sup>R<sup>14</sup>NC(S)-;

$R^8$  is selected from the group consisting of: H, C<sub>1</sub>-6alkyl, C<sub>2</sub>-6alkenyl, C<sub>2</sub>-6alkynyl, HetC<sub>0</sub>-6alkyl and ArC<sub>0</sub>-6alkyl;

$R^9$  is selected from the group consisting of: C<sub>1</sub>-6alkyl, C<sub>3</sub>-6cycloalkyl-C<sub>0</sub>-6alkyl, Ar-C<sub>0</sub>-6alkyl and Het-C<sub>0</sub>-6alkyl;

$R^{10}$  is selected from the group consisting of: C<sub>1</sub>-6alkyl, C<sub>3</sub>-6cycloalkyl-C<sub>0</sub>-6alkyl, Ar-C<sub>0</sub>-6alkyl and Het-C<sub>0</sub>-6alkyl;

$R^{11}$  is selected from the group consisting of: H, C<sub>1</sub>-6alkyl, Ar-C<sub>0</sub>-6alkyl, and Het-C<sub>0</sub>-6alkyl;

$R^{12}$  is selected from the group consisting of: H, C<sub>1</sub>-6alkyl, Ar-C<sub>0</sub>-6alkyl, and Het-C<sub>0</sub>-6alkyl;

$R^{13}$  is selected from the group consisting of: H, C<sub>1</sub>-6alkyl, Ar-C<sub>0</sub>-6alkyl, and Het-C<sub>0</sub>-6alkyl;

$R^{14}$  is selected from the group consisting of: H, C<sub>1</sub>-6alkyl, Ar-C<sub>0</sub>-6alkyl, and Het-C<sub>0</sub>-6alkyl;

Predecessor Serial No.: 10/258,053

Group Art Unit No.:

R' is selected from the group consisting of: H, C<sub>1-6</sub>alkyl, Ar-C<sub>0-6</sub>alkyl, and Het-C<sub>0-6</sub>alkyl;


R" is selected from the group consisting of: H, C<sub>1-6</sub>alkyl, Ar-C<sub>0-6</sub>alkyl, or Het-C<sub>0-6</sub>alkyl;

R'" is selected from the group consisting of: H, C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl-C<sub>0-6</sub>alkyl, Ar-C<sub>0-6</sub>alkyl, and Het-C<sub>0-6</sub>alkyl;

X is selected from the group consisting of: CH<sub>2</sub>, S, and O;

Z is selected from the group consisting of: C(O) and CH<sub>2</sub>;

and pharmaceutically acceptable salts, hydrates and solvates thereof.



2. A method according to Claim 1 wherein in said compound R<sup>1</sup> is .

3. A method according to Claim 2 wherein in said compound R<sup>3</sup> is C<sub>3-6</sub>cycloalkyl-C<sub>0-6</sub>alkyl.

4. A method according to Claim 3 wherein in said compound R<sup>3</sup> is cyclohexylmethyl.

5. A method according to Claim 2 wherein in said compound R<sup>4</sup> is R<sup>5</sup>C(O)-.

6. A method according to Claim 5 wherein in said compound R<sup>5</sup> is selected from the group consisting of: C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl-C<sub>0-6</sub>alkyl, Ar-C<sub>0-6</sub>alkyl and Het-C<sub>0-6</sub>alkyl.

7. A method according to Claim 6 wherein in said compound R<sup>5</sup> is selected from the group consisting of:

furanyl;

benzofuranyl;

thiophenyl;

furo[3,2-b]-pyridine-2-yl;

thiazolyl;

phenyl;

Predecessor Serial No.: 10/258,053

Group Art Unit No.:

cyclobutyl;  
cyclopentyl;  
tetrahydrofuryl;  
selenophenyl; and  
thieno[3,2-b]thiophenyl.

8. A method according to Claim 6 wherein in said compound R<sup>5</sup> is selected from the group consisting of:

furan-2-yl and furan-3-yl;  
benzofuran-2-yl;  
thiophene-3-yl and thiophene-2-yl;  
furo[3,2-b]-pyridine-2-yl;  
thiazole-5-yl;  
tetrahydrofuran-2-yl;  
selenophene-2-yl; and  
thieno[3,2-b]thiophene-2-yl.

9. A method according to Claim 6 wherein in said compound R<sup>5</sup> is selected from the group consisting of:

aryl substituted furanyl;  
C<sub>1</sub>-6alkoxy substituted benzofuranyl;  
Het-C<sub>0</sub>-6alkyl-thiophenyl, C<sub>1</sub>-6alkyl-thiophenyl and C<sub>1</sub>-6alkoxy-thiophenyl,  
C<sub>1</sub>-6alkyl-furo[3,2-b]-pyridine-2-yl,  
Het-C<sub>0</sub>-6alkyl-thiazolyl; and  
halogen substituted phenyl.

10. A method according to Claim 6 wherein in said compound R<sup>5</sup> is selected from the group consisting of:

5-(3-trifluoromethyl-phenyl)-furan-2-yl and 5-(4-chloro-phenyl)-furan-2-yl;  
5,6-dimethoxy-benzofuran-2-yl and 5-(2-morpholin-4-yl-ethoxy)benzofuran-2-yl;

Predecessor Serial No.: 10/258,053

Group Art Unit No.:

5-pyridin-2-yl- thiophene-2-yl, 5-methyl-thiophene-2-yl, 3-methyl-thiophene-2-yl; and 3-ethoxy-thiophene-2-yl;  
3-methyl-furo[3,2-b]-pyridine-2-yl;  
4-methyl-2-pyridin-2-yl-thiazole-5-yl; and  
4-bromophenyl.

11. A method according to Claim 1 wherein in said compound R' is H.
12. A method according to Claim 1 wherein in said compound R" is H.
13. A method according to Claim 1 wherein in said compound R'" is selected from the group consisting of: H and C<sub>1-6</sub>alkyl.
14. A method according to Claim 1 wherein in said compound R" is H and R'" is selected from the group consisting of: H and C<sub>1-6</sub>alkyl.
15. A method according to Claim 13 wherein in said compound R'" is H.
16. A method according to Claim 13 wherein in said compound R'" is C<sub>1-6</sub>alkyl.
17. A compound according to Claim 16 wherein C<sub>1-6</sub>alkyl is selected from the group consisting of: 5-, 6- and 7-C<sub>1-6</sub>alkyl.
18. A compound according to Claim 17 wherein 5-, 6- and 7-C<sub>1-6</sub>alkyl is selected from the group consisting of: 5-, 6- or 7- methyl, -ethyl, -propyl, -butyl, -pentyl, and -hexyl.
19. A compound according to Claim 21 wherein 5-, 6- and 7-C<sub>1-6</sub>alkyl is selected from the group consisting of: 5-, 6- and 7-methyl.
20. A compound according to Claim 16 wherein C<sub>1-6</sub>alkyl is selected from the group consisting of: 6- and 7-C<sub>1-6</sub>alkyl.

Predecessor Serial No.: 10/258,053

Group Art Unit No.:

21. A compound according to Claim 20 wherein 6- and 7-C<sub>1</sub>-6alkyl is selected from the group consisting of: 6- or 7- methyl, -ethyl, -propyl, -butyl, -pentyl, and -hexyl.


22. A compound according to Claim 21 wherein 6- and 7-C<sub>1</sub>-6alkyl is selected from the group consisting of: 6- and 7-methyl.

23. A compound according to Claim 16 wherein C<sub>1</sub>-6alkyl is 7-C<sub>1</sub>-6alkyl.

24. A compound according to Claim 23 wherein 7-C<sub>1</sub>-6alkyl is selected from the group consisting of: 7- methyl, -ethyl, -propyl, -butyl, -pentyl, and -hexyl.

25. A compound according to Claim 24 wherein 7-C<sub>1</sub>-6alkyl is 7-methyl.

26. A compound according to Claim 16 of Formula Ia:



Ia

wherein R'' is *cis*-7-C<sub>1</sub>-6alkyl.

27. A compound according to Claim 26 wherein R'' is *cis*-7-methyl.

28. A method according to Claim 1 wherein in said compound R<sup>2</sup> is R<sup>9</sup>SO<sub>2</sub>.

29. A method according to Claim 28 wherein in said compound R<sup>9</sup> is Het-C<sub>0</sub>-6alkyl.

30. A method according to Claim 29 wherein Het-C<sub>0</sub>-6alkyl is selected from the group consisting of: pyridinyl and 1-oxy-pyridinyl.


Predecessor Serial No.: 10/258,053

Group Art Unit No.:

31. A method according to Claim 30 wherein R<sup>9</sup> is pyridin-2-yl.

32. A method according to Claim 1 wherein in said compound:

R<sup>1</sup> is



R<sup>2</sup> is R<sup>9</sup>SO<sub>2</sub>;

R<sup>3</sup> is C<sub>3-6</sub>cycloalkyl-C<sub>0-6</sub>alkyl;

R<sup>4</sup> is R<sup>5</sup>C(O);

R<sup>5</sup> is Het-C<sub>0-6</sub>alkyl;

R<sup>9</sup> is Het-C<sub>0-6</sub>alkyl;

R' is H

R'' is H; and

R''' is C<sub>1-6</sub>alkyl.

33. A method according to Claim 1 wherein in said compound:


R<sup>3</sup> is cyclohexylmethyl;

R<sup>5</sup> is selected from the group consisting of: furan-2-yl and thiophene-3-yl;

R<sup>9</sup> is pyridin-2-yl; and

R''' is 7-methyl.


34. A method according to Claim 1 wherein said compound is selected from the group consisting of:




Benzofuran-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;

Predecessor Serial No.: 10/258,053


Group Art Unit No.:




5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




5-(4-Chloro-phenyl)-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;



5-(4-Chloro-phenyl)-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




5,6-Dimethoxy-benzofuran-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide; and

Predecessor Serial No.: 10/258,053


Group Art Unit No.:




furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;



benzofuran-2-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;




thiophene-3-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;




3-methyl-furo[3,2-b]- pyridine-2-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;

Predecessor Serial No.: 10/258,053


Group Art Unit No.:




5-(2-morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




4-methyl-2-pyridin-2-yl-thiazole-5-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;



5-pyridin-2-yl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;

Predecessor Serial No.: 10/258,053


Group Art Unit No.:




thiophene-3-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




5-methyl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;



3-methyl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




3-ethoxy-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




Predecessor Serial No.: 10/258,053

Group Art Unit No.:


4-bromo-N-((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-benzamide;




cyclobutanecarboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




cyclopentanecarboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;



(S)-tetrahydro-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




(R)-tetrahydro-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




furan-3-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;

Predecessor Serial No.: 10/258,053


Group Art Unit No.:




5-pyridin-2-yl-thiophene-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;




4-methyl-2-pyridin-2-yl-thiazole-5-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;



5-(2-morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;




furan-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;




furan-3-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;

Predecessor Serial No.: 10/258,053


Group Art Unit No.:




thiophene-3-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;



5-methyl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




3-methyl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




3-ethoxy-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;

Predecessor Serial No.: 10/258,053


Group Art Unit No.:




selenophene-2-carboxylic acid [(S)-2-cyclohexyl-1-[(R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl]-amide;




furan-2-carboxylic acid [(S)-2-cyclohexyl-1-((4S,7R)-7-methyl-3-oxo-1-propyl-azepan-4-ylcarbamoyl)-ethyl]-amide;



thiophene-3-carboxylic acid [(S)-2-cyclohexyl-1-((4S,7R)-7-methyl-3-oxo-1-propyl-azepan-4-ylcarbamoyl)-ethyl]-amide;




benzofuran-2-carboxylic acid [(S)-2-cyclohexyl-1-((4S,7R)-7-methyl-3-oxo-1-propyl-azepan-4-ylcarbamoyl)-ethyl]-amide;




2,2,4-trideutero-Furan-2-carboxylic acid [(S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl]-amide;

Predecessor Serial No.: 10/258,053


Group Art Unit No.:



thiophene-3-carboxylic acid ((S)-3,3-dimethyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl)-amide;




furan-2-carboxylic acid ((S)-3,3-dimethyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl)-amide; and



thieno[3,2-b] thiophene-2-carboxylic acid ((S)-3,3-dimethyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl)-amide.


35. A compound according to Claim 34 selected from the group consisting of:



furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide; and


Predecessor Serial No.: 10/258,053

Group Art Unit No.:



thiophene-3-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide.

36. A compound according to Claim 35 which is:



furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide.

37. (Amended) A method of treatment and prevention of an autoimmune disease comprising inhibiting overexpression of cathepsin S by administering to a patient in need thereof an effective amount of a compound according to ~~any one of Claims 1 to 36~~Claim 1.

38. A method according to Claim 37 wherein said disease is selected from the group consisting of : rheumatoid arthritis, multiple sclerosis, juvenile-onset diabetes, systemic lupus erythematosus, discoid lupus erythematosus, pemphigus vulgaris, pemphigoid, Grave's disease, myasthenia gravis, Hashimoto's thyroiditis, scleroderma, dermatomyositis, Addison's disease, pernicious anemia, primary myxoedema, thyrotoxicosis, autoimmune atrophic gastritis, stiff-man syndrome, Goodpasture's syndrome, sympathetic ophthalmia, phacogenic uveitis, autoimmune haemolytic anaemia, idiopathic thrombocytopenic purpura, idiopathic leucopenia, primary biliary cirrhosis, active chronic hepatitis, cryptogenic cirrhosis, ulcerative colitis, Sjogren's syndrome, and mixed connective tissue disease.

39. (Amended) A method of treatment or prevention of a disease state caused by the formation or complications of atherosclerotic lesions comprising inhibiting formation of said lesions or complications thereof by administering to a patient in need thereof an effective amount of a compound according to ~~any one of Claims 1 to 36~~Claim 1.

Predecessor Serial No.: 10/258,053

Group Art Unit No.:

40. (Amended) A method of treatment of a disease which requires for therapy inhibition of a class II MHC-restricted immune response, comprising inhibiting said class II MHC-restricted immune response by administering to a patient in need thereof an effective amount of a compound according to ~~any one of Claims 1 to 36~~Claim 1.

41. (Amended) A method of treatment of a disease which requires for therapy inhibition of an asthmatic response, comprising inhibiting said asthmatic response by administering to a patient in need thereof an effective amount of a compound according to ~~any one of Claims 1 to 36~~Claim 1.

42. (Amended) A method of treatment of a disease which requires for therapy inhibition of an allergic response, comprising inhibiting said allergic response by administering to a patient in need thereof an effective amount of a compound according to ~~any one of Claims 1 to 36~~Claim 1.

43. (Amended) A method of treatment of a disease which requires for therapy inhibition of an immune response against a transplanted organ or tissue, comprising inhibiting said immune response against a transplanted organ or tissue by administering to a patient in need thereof an effective amount of a compound according to ~~any one of Claims 1 to 36~~Claim 1.

44. (Amended) A method of treatment of a disease which requires for therapy inhibition of elastase activity in atheroma, comprising inhibiting said elastase activity in atheroma by administering to a patient in need thereof an effective amount of a compound according to ~~any one of Claims 1 to 36~~Claim 1.

45. (Cancelled)

46. (Cancelled)

47. (Cancelled)

48. (Cancelled)

49. (Cancelled)

50. (Cancelled)

51. (Cancelled)

52. (Cancelled)

53. (Cancelled)